Scancell ends clinical development partnership with Cancer Research UK
3rd Feb 2021 14:53
(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.
Read moreScancell selects Covid-19 vaccine candidate for development and trials
18th Dec 2020 10:17
(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.
Read moreScancell reaches Covid-19 collaboration agreement with Cobra Biologics
2nd Oct 2020 09:18
(Sharecast News) - Immunotherapies developer Scancell Holdings has entered into a collaboration agreement with Cobra Biologics to manufacture the firm's Covid-19 vaccine.
Read moreScancell upbeat on publication of AvidiMab research
12th Jun 2020 12:59
(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.
Read moreDirector dealings: Scancell director lowers stake
28th Apr 2020 16:40
(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.
Read moreScancell's 'SCIB1' clears latest regulatory hurdle in US
3rd Feb 2020 14:20
(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.
Read moreScancell inks AvidiMab agreement with Chinese biotech company
16th Dec 2019 13:30
(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.
Read moreScancell signs collaboration agreement with antibody technology company
4th Sep 2019 08:58
(Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.
Read moreScancell losses deepen as it presses on with development
20th Aug 2019 10:59
(Sharecast News) - Novel immunotherapies developer Scancell Holdings reported a deeper operating loss in its final results on Tuesday, to £6.73m compared to £4.91m in the 2018 financial year.
Read moreScancell to begin SCIB1 UK trial as FDA issues linger in US
19th Aug 2019 09:33
(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.
Read moreScancell partnership with Cancer Research moves closer to clinic
20th May 2019 11:03
(Sharecast News) - Immunotherapy developer Scancell Holdings updated the market on its clinical development partnership with Cancer Research UK for the development of the ;ImmunoBody' vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), on Monday.
Read moreScancell gets go-ahead for UK second phase trials of 'SCIB1'
25th Apr 2019 11:19
(Sharecast News) - Cancer immunotherapy developer Scancell Holdings has received all of the UK regulatory, ethical and legal approvals required to initiate the phase 2 clinical trial to assess the safety and efficacy of 'SCIB1' in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda), it announced on Thursday.
Read moreScancell Holdings expands IP protection with Japanese patent
8th Apr 2019 11:34
(Sharecast News) - Scancell Holdings on Monday won a Japanese patent for its Moditope immunotherapy platform, which stimulates the production of cells that overcome the immune suppression induced by tumours.
Read moreScancell shares slip as losses widen in first half
31st Jan 2019 09:48
(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.
Read moreScancell loses out on Cancer Research UK grant
23rd Jan 2019 11:20
(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.
Read more